Clinical trials: Vitrectomy
Vitrectomy
The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)
To evaluate the pharmacokinetic properties of intravitreal ocriplasmin 125 µg dose when administered at different time-points prior to planned primary pars plana vitrectomy (PPV)
- Trial name
- MIVI-10 (NCT01159665)
- Testing
- ocriplasmin
- Where
- Belgium
- Volunteers
- 38 people
- Sponsor
- ThromboGenics
Vitrectomy
Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to…
- Trial name
- NCT01229410
- Testing
- 400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
- Where
- 2 sites in United States, Czechia
- Volunteers
- 24 people
- Sponsor
- Allergan
Vitreo-retinal Surgery
A Phase I Study of Vitargus® in Vitrectomy
A Phase I, safety and tolerability study of Vitargus® in vitrectomy surgery
- Trial name
- NCT04481386
- Testing
- Vitargus, BFC-1401
- Where
- Australia
- Volunteers
- 11 people
- Sponsor
- BioFirst Corporation
Eye Diseases
Next Generation Ophthalmic Irrigating Solution Posterior Segment Study
The purpose of this study is to evaluate the safety of Next Generation Ophthalmic Irrigating Solution (NGOIS) compared to BSS PLUS for use during surgery for removal of epimacular membrane and vitrectomy.
- Trial name
- NCT00333203
- Testing
- Next Generation Ophthalmic Irrigating Solution (NGOIS), BSS Plus
- Where
- United States
- Volunteers
- 369 people
- Sponsor
- Alcon Research
Symptomatic Vitreomacular Adhesion
A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion
The purpose of this study is to evaluate the superiority regarding vitreomacular adhesion (VMA) resolution of a single intravitreal injection of A01016 (Ocriplasmin) compared to sham-injection in subjects with symptomatic VMA.
- Trial name
- NCT01889251
- Testing
- Ocriplasmin
- Where
- Japan
- Volunteers
- 251 people
- Sponsor
- Alcon Research
Vitrectomy
Clinical Trial of Intravitreal Microplasmin in Infants and Children Scheduled for Vitrectomy
To evaluate the safety and preliminary efficacy of intravitreal microplasmin as an adjunct to conventional vitrectomy for the treatment of pediatric patients.
- Trial name
- MIC (NCT00986362)
- Testing
- Ocriplasmin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- ThromboGenics
Cataract, Vitrectomy
Clinical Study to Confirm the Safety and Performance of the Virtuoso Phaco-vitrectomy Device
This is a pre-market clinical investigation with a device that does not bear the CE-marking. Aim of the study is to confirm the safety and performance of the device and collect user feedback.
- Conditions
- Cataract, Vitrectomy, Vitrectomy Operation Under General Anesthesia
- Trial name
- Virtuoso1 (NCT06799156)
- Where
- Germany
- Volunteers
- 205 people
- Sponsor
- Beaver-Visitec International, Inc.
Vitrectomy
A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)
A multicenter study to compare multiple doses of intravitreal microplasmin in patients undergoing surgical vitrectomy.
- Trial name
- NCT00412958
- Testing
- Ocriplasmin 25µg, Ocriplasmin 75µg, Ocriplasmin 125µg
- Where
- 20 sites in United States
- Volunteers
- 125 people
- Sponsor
- ThromboGenics
Vitrectomy
A Study to Evaluate the Safety and Performance of the Vista Probe for Vitrectomy Surgery
This is a prospective, single-arm, non-comparative, open-label, monocular, post approval study to assess safety and device performance of the Vista Vitrectomy Probe during vitrectomy surgery.
- Trial name
- NCT05689333
- Testing
- Vista Vitrectomy Probe
- Where
- 4 sites in United States
- Volunteers
- 32 people
- Sponsor
- VISTA Ophthalmics
Diabetic Macular Edema, Vitrectomy
Safety and Efficacy of a New Treatment in Vitrectomized Subjects With Diabetic Macular Edema
The study will evaluate the safety and efficacy of the intravitreal dexamethasone implant in the study eye of vitrectomized subjects with diabetic macular edema. Subjects will be followed for 26 weeks.
- Trial name
- NCT00799227
- Testing
- Dexamethasone
- Where
- 2 sites in United States, Australia
- Volunteers
- 56 people
- Sponsor
- Allergan
Vitrectomy
Comparison of Vitreous Levels of Acular LS 0.04%, Xibrom 0.09%, and Nevanac 0.1%
To compare the penetration of three different NSAIDs.
- Trial name
- NCT00377546
- Testing
- Nepafenac, Ketorolac LS, Bromfenac
- Where
- United States
- Sponsor
- Innovative Medical
Vitreomacular Traction, Vitreomacular Adhesion
Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion
The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA™®) over a 6-month period.
- Trial name
- NCT02322229
- Testing
- Ocriplasmin 0.125 mg in a 0.1 mL volume
- Where
- Australia
- Volunteers
- 62 people
- Sponsor
- Alcon Research
Diabetes
A Phase 2 Study of the Safety and Efficacy of Thymosin Beta 4 for Treating Corneal Wounds
As a consequence of damage to multiple organ systems throughout the course of their disease, diabetic patients suffer a number of chronic complications giving rise to increased morbidity, mortality, and health care costs specific…
- Trial name
- NCT00598871
- Testing
- Thymosin Beta 4 (Tβ4)
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- ReGenTree, LLC
Cataract
Ocular Biodistribution Study for Topically Applied ESBA105
The purpose of this study is to determine whether ESBA105, a single-chain (scFv) antibody against TNF-alpha, efficiently penetrates into the anterior chamber and the vitreous body upon topical administration to the eye.
- Trial name
- NCT00820014
- Where
- 2 sites in Switzerland
- Volunteers
- 79 people
- Sponsor
- ESBATech AG
Vitrectomy
Safety and Efficacy of Vitreous Delineating Agent During Vitrectomy
The purpose of this study is to evaluate the safety and efficacy of triamcinolone acetonide suspension when used for visualization of structures in the back of the eye during eye surgery.
- Trial name
- NCT00532415
- Testing
- Triamcinolone Acetonide Injectable Suspension
- Volunteers
- 60 people
- Sponsor
- Alcon Research
Vitreomacular Traction Maculopathy, Eye Diseases
Intravitreal Microplasmin in Patients Undergoing Surgical Vitrectomy
The purpose of this trial is to evaluate the safety and preliminary efficacy of different doses and several exposure times of intravitreal microplasmin in the setting of pars plana vitrectomy for vitreomacular traction…
- Trial name
- NCT00123279
- Testing
- Microplasmin
- Where
- 3 sites in Belgium, Netherlands
- Volunteers
- 60 people
- Sponsor
- ThromboGenics
Vitrectomy
Observational Study of Ocular Inflammation in Patients Undergoing a Pars Plana Vitrectomy
This study will evaluate the degree of post-operative ocular inflammation in patients who are undergoing a pars plana vitrectomy.
- Trial name
- NCT01319318
- Testing
- Pars Plana Vitrectomy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Allergan
Epiretinal Membrane, Macular Hole
Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal
The purpose of this trial is to compare the ability of two doses of OT-551 ophthalmic solution and drug-free solution to safely and effectively prevent or delay the progression of nuclear cataracts that frequently develop as a…
- Trial name
- NCT00333060
- Testing
- OT-551 ophthalmic solution
- Where
- 16 sites in United States
- Volunteers
- 164 people
- Sponsor
- Othera Pharmaceuticals
Epiretinal Membrane
Role of Nepafenac in Reducing Macular Volume After Epiretinal Membrane Surgery
The purpose of this study is to compare the macular volume of patients treated with a 3-month course of topical Nepafenac (0.1% solution) to patients treated with a placebo course following epiretinal membrane surgery.
- Trial name
- NCT00818844
- Testing
- Nepafenac 0.1%, BSS
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Alcon Research
Cataract
NPI-002 Intravitreal Implant for the Delay of Cataract Progression
This study will examine the safety and efficacy NPI-002 intravitreal implants post vitrectomy.
- Trial name
- NCT05026632
- Testing
- NPI-002 Intravitreal Implant
- Where
- Australia
- Volunteers
- 24 people
- Sponsor
- Nacuity Pharmaceuticals, Inc.